Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct 30;5(1):251.
doi: 10.1038/s41392-020-00364-8.

Cancer vaccines: shared tumor antigens return to the spotlight

Lijin Li  1 , S Peter Goedegebuure  1   2 , William Gillanders  3   4
Affiliations
Comment

Cancer vaccines: shared tumor antigens return to the spotlight

Lijin Li et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Melanoma RNA-LPX vaccine targeting TAA induces antitumor immunity in ICB-experienced patients. The lipid-formulated vaccine is composed of RNA encoding multiple TAAs. RNA vaccine stimulates TLR7, which results in systemically increased production of pro-inflammatory cytokines. RNA-LPX are taken up by DCs and the antigens are presented to T cells in the context of HLA class I and class II molecules. Combined with PD1 blockade, the off-shelf TAA-targeting RNA vaccine can lead to favorable clinical outcomes. Further studies are required to determine the optimal strategy for integrating cancer vaccines into clinical treatment paradigms
See this image and copyright information in PMC

Comment on

  • An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.
    Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, Kranz LM, Diken M, Kreiter S, Haas H, Attig S, Rae R, Cuk K, Kemmer-Brück A, Breitkreuz A, Tolliver C, Caspar J, Quinkhardt J, Hebich L, Stein M, Hohberger A, Vogler I, Liebig I, Renken S, Sikorski J, Leierer M, Müller V, Mitzel-Rink H, Miederer M, Huber C, Grabbe S, Utikal J, Pinter A, Kaufmann R, Hassel JC, Loquai C, Türeci Ö. Sahin U, et al. Nature. 2020 Sep;585(7823):107-112. doi: 10.1038/s41586-020-2537-9. Epub 2020 Jul 29. Nature. 2020. PMID: 32728218 Clinical Trial.

References

    1. Sahin U, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585:107–112. doi: 10.1038/s41586-020-2537-9. - DOI - PubMed
    1. Romero P, et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci Transl Med. 2016;8:334ps339. doi: 10.1126/scitranslmed.aaf0685. - DOI - PubMed
    1. Kranz LM, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396–401. doi: 10.1038/nature18300. - DOI - PubMed
    1. Verma V, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 2019;20:1231–1243. doi: 10.1038/s41590-019-0441-y. - DOI - PMC - PubMed
    1. Mohsen MO, et al. Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine. Front. Immunol. 2019;10:1015. doi: 10.3389/fimmu.2019.01015. - DOI - PMC - PubMed